Here are five things to know about the transaction:
• The shares were sold at $35.14 average price.
• The total transaction is valued at $87,850.
• Mr. Valentine now directly owns 77,285 shares of the company.
• The shares Mr. Valentine currently owns are valued at $2.7 million.
• After the transaction, NuVasive traded up 1.02 percent mid-day on Wednesday, hitting $35.40.
NuVasive reported a solid second quarter of 2014, with $190 million in revenue and adjusted their full-year predictions. The company now estimates 2014 revenue will reach $745 million, a 9 percent growth over 2013.
At the end of July, Jeffries Group gave NuVasive a “buy” rating and Barclays reiterated an “equal weight” rating. At the same time, Goldman Sachs upgraded NuVasive from “neutral” to “buy.”
In early August, NuVasive CFO Micahel Lambert sold 4,010 shares of the company’s stock in a $148,811 transaction. Executive Vice President Russell Powers sold 12,776 shares of the company stock this past summer as well.
More articles for orthopedic devices:
15 spine devices receive FDA 510(k) clearance
Zacks: Pay attention to these 3 medical device stocks
8 things to know about the Asia-Pacific minimally invasive spine device market
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
